25 citations
,
May 2018 in “Clinical & Translational Oncology” This review summarizes common skin-related side effects of BRAF inhibitors and immunotherapy in advanced melanoma treatment, reporting no new clinical findings, and emphasizes consensus management to improve patient outcomes.
March 2023 in “International Journal of Trichology” This case report describes the first known occurrence of alopecia areata associated with cemiplimab, an anti-PD1 drug, in a patient with a positive cancer treatment response.
April 2016 in “Journal of Investigative Dermatology” This study found that the peptide derivative beta-Ala-Pro-Dab-NHbenzyl may reduce wrinkles and sebum production in human skin by inhibiting dipeptidyl peptidase 4, suggesting potential for acne and skin inflammation treatment.
12 citations
,
March 2021 in “JAAD Case Reports” This study reported that immunotherapy in cancer patients can lead to skin-related immune adverse events, such as rashes, pruritus, and vitiligo, affecting a substantial proportion of patients.
1 citations
,
December 2023 in “Nanomaterials” In this study, the researchers synthesized copper-doped mesoporous silica nanoparticles and observed that they enhance tumor microenvironment regulation and, when paired with disulfiram, effectively kill cancer cells while also showing synergistic anti-tumor effects with immune checkpoint inhibitors.
